Trade Apellis Pharmaceuticals, Inc. - APLS CFD

Add to favourite

27.46

2.93%

0.12

Low: 27.42

High: 28.63

Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

Summary
Historical Data

Trading сonditions

Spread

0.12

Long position overnight fee

-0.023512%

Short position overnight fee

0.00129%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

50.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	28.29
Open	28.63
1-Year Change	-36.31%
Day's Range	27.42 - 28.63

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Feb 21, 2025	27.46	-0.89	-3.14%	28.35	28.72	27.39
Feb 20, 2025	28.29	-0.19	-0.67%	28.48	28.84	27.84
Feb 19, 2025	28.31	0.46	1.65%	27.85	28.39	27.85
Feb 18, 2025	28.11	0.70	2.55%	27.41	28.49	27.41
Feb 14, 2025	27.32	-0.13	-0.47%	27.45	28.14	26.97
Feb 13, 2025	27.41	-1.12	-3.93%	28.53	28.53	26.79
Feb 12, 2025	28.46	0.79	2.86%	27.67	28.47	27.53
Feb 11, 2025	28.46	0.22	0.78%	28.24	29.04	28.23
Feb 10, 2025	28.62	-0.72	-2.45%	29.34	29.55	28.49
Feb 7, 2025	29.32	0.12	0.41%	29.20	30.15	28.99
Feb 6, 2025	30.10	-0.16	-0.53%	30.26	30.35	29.47
Feb 5, 2025	30.30	1.54	5.35%	28.76	30.50	28.71
Feb 4, 2025	28.70	0.15	0.53%	28.55	29.05	28.17
Feb 3, 2025	28.44	0.17	0.60%	28.27	28.77	27.83
Jan 31, 2025	28.93	-1.33	-4.40%	30.26	30.46	28.91
Jan 30, 2025	30.32	1.17	4.01%	29.15	30.44	28.99
Jan 29, 2025	29.39	0.24	0.82%	29.15	29.75	28.97
Jan 28, 2025	29.23	-0.62	-2.08%	29.85	29.85	28.65
Jan 27, 2025	29.72	0.09	0.30%	29.63	30.70	29.30
Jan 24, 2025	29.95	-0.42	-1.38%	30.37	30.80	29.61

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

2:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam''s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Industry:

Biopharmaceuticals

100 Fifth Avenue
WALTHAM
MASSACHUSETTS 02451
US

News

Microsoft Stock Price Forecast for 2025 and beyond: Third party price target

We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...

18:29, 7 February 2025

Ripple XRP price prediction: Third-party price target

Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com

15:29, 6 February 2025

Apple Store on Fifth Avenue, New York, October 2016

Apple (AAPL) stock price forecast: third-party price target

We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.

11:22, 6 February 2025